Search by Drug Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y ZClinical Trials for SELPERCATINIB
- A Drug Drug Interaction (DDI) Study of Selpercatinib (LY3527723) and Rosuvastatin in Healthy Participants
- Restor. I-131 Upt. + Selpercatinib in RET F-P RAI-R TC
- A Study of Absorption, Metabolism, Excretion, and Absolute Bioavailability of Carbon-14-Labelled [14C] Selpercatinib (LY3527723) in Healthy Male Participants
- A Study of Effect of Selpercatinib (LY3527723) on Corrected QT (QTc) Interval in Healthy Participants
- A Study of Effects of Selpercatinib (LY3527723) on Repaglinide in Healthy Participants
- A Study of Effect of Selpercatinib (LY3527723) in Participants With Normal and Impaired Renal Function
- A Study of Effect of Food and a Proton Pump Inhibitor on Selpercatinib (LY3527723) in Healthy Participants
- A Study of Effects of Selpercatinib in Hepatically Impaired Participants and Healthy Participants
- A Randomized Phase II Study of Carboplatin and Pemetrexed With or Without Selpercatinib in Patients With Non-squamous RET Positive Stage IV Non-small Cell Lung Cancer and Progression of Disease on Prior RET Directed Therapy, A Lung-MAP Treatment Tri
- A Study of Selpercatinib (LY3527723) in Healthy Participants
- Study of H2 Antagonist and a Proton Pump Inhibitor of Selpercatinib in Healthy Participants
- A Study of Effects of Itraconazole and Rifampin on Selpercatinib (LY3527723) in Healthy Participants
- A Study of Effects of Selpercatinib (LY3527723) on Midazolam in Healthy Participants
- A Study of the Effect of Food on Selpercatinib (LY3527723) in Healthy Participants
- A Relative Bioavailability Study of Selpercatinib (LY3527723) in Healthy Participants
- A Study Comparing Two Formulations of Selpercatinib (LY3527723) in Healthy Participants
- A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC)
- A Drug Drug Interaction (DDI) Study of Selpercatinib and Dabigatran in Healthy Participants
- Selpercatinib Before Surgery for the Treatment of RET-Altered Thyroid Cancer
- Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene Alterations, a Pediatric MATCH Treatment Trial
- A Study of Selpercatinib (LY3527723) in Participants With Advanced Solid Tumors Including RET Fusion-positive Solid Tumors, Medullary Thyroid Cancer and Other Tumors With RET Activation
- Targeted Treatment for RET Fusion-Positive Advanced Non-Small Cell Lung Cancer (A LUNG-MAP Treatment Trial)
- A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer
- A Study of Selpercatinib (LY3527723) in Participants With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer
- Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD)
- A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) Tumors
- A Study of LOXO-292 in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer
- Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)
Clinical trials list
click for details